Business Context and Reporting Period
Company: ENDRA Life Sciences Inc. (NDRA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: ENDRA is developing a Thermo-Acoustic Enhanced Ultrasound (TAEUS) platform to measure liver fat for metabolic disease management and GLP-1 drug monitoring. The company has pivoted its strategy to focus on a subscription-based business model targeting pharmaceutical companies, clinical research organizations, and primary care networks. As of the reporting date, the company has not generated product revenue and is pre-commercialization.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11,507,947) | $(10,060,250) |
| Operating Expenses | $10,817,147 | $10,520,735 |
| Cash and Cash Equivalents (End of Period) | $3,229,480 | $2,833,907 |
| Accumulated Deficit | $(103,438,099) | $(91,930,152) |
| Working Capital | $2,828,435 | $2,129,717 |
Note: The company reported no revenue or cost of goods sold for either period. The increase in net loss in 2024 was driven by a significant inventory reserve charge and warrant-related expenses.
Material Changes vs. Prior Period
- Inventory Write-down: General and Administrative expenses increased by 50% to $7.1 million, primarily due to a non-cash inventory reserve charge of $2.5 million. Management determined existing inventory was obsolete following a strategic decision to redesign the TAEUS liver system to be smaller, simpler, and more cost-effective.
- Warrant Liability: The company recognized $7.3 million in warrant expense and a $3.4 million gain from changes in the fair value of warrant liability, alongside a $3.1 million gain on the settlement of warrant exercises. These items resulted in a net "Other Expense" of $690,800 for 2024, compared to "Other Income" of $460,485 in 2023.
- Stock Structure: The company executed two reverse stock splits in 2024 (1-for-50 in August and 1-for-35 in November) to regain compliance with Nasdaq minimum bid price requirements.
- Leadership Transition: In August 2024, the former CEO and CFO resigned. Alexander Tokman was appointed Acting CEO and Chairman, and Richard Jacroux was appointed CFO.
Outlook, Risks, and Contingencies
- Going Concern: The independent auditor has raised substantial doubt about the company's ability to continue as a going concern. With cash of approximately $3.2 million and a net loss of $11.5 million in 2024, the company requires additional capital to fund operations for the next 12 months.
- Regulatory Status:
- EU: Holds a CE Mark for the TAEUS liver device (Class IIa) but must transition to the new Medical Device Regulation (MDR) by December 31, 2028. Audits were successfully concluded in November 2024.
- US: A De Novo request to the FDA was closed in April 2024 after an Additional Information request. The company plans to submit a new De Novo request following the completion of a new clinical study.
- Capital Needs: The company is actively exploring financing options, including its At-The-Market (ATM) equity offering program, private placements, and strategic collaborations. Failure to secure funding could force the company to curtail operations or cease business.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to insufficient personnel resources to segregate duties in the accounting function.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $3.2 million cash balance against the projected burn rate and the timeline for the next capital raise.
- Inventory Obsolescence: Confirm the extent of the $2.5 million inventory write-off and the status of the redesigned TAEUS system.
- Regulatory Timeline: Monitor the progress of the new clinical study required for the FDA De Novo submission and the MDR transition timeline in the EU.
- Warrant Dilution: Review the terms of the Series A and Series B warrants, including the cashless exercise provisions and potential dilution impact on existing shareholders.
- Nasdaq Compliance: Track the stock price to ensure continued compliance with Nasdaq minimum bid price requirements following the recent reverse splits.